SCHEMBL25879861

SCHEMBL25879861

Cc1cc(O)c(C(C)C)c(F)c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
BCL2 P10415 1/20 0.38
BCL2L1 Q07817 1/20 0.38
MCL1 Q07820 1/20 0.38
BCL2L2 Q92843 1/20 0.38
TRPA1 O75762 2/20 0.36
PTGS1 P23219 1/20 0.36
CACNA1C Q13936 1/20 0.36
CHRM1 P11229 1/20 0.36
SLC6A2 P23975 1/20 0.36
ADRA1A P35348 1/20 0.36
HTR2B P41595 1/20 0.36
ACHE P22303 1/20 0.36
AHR P35869 1/20 0.35
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
PKM P14618 2/20 0.33
KDM4E B2RXH2 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12572590 0.85 ACHE (0.37) LMNABCL2BCL2L1MCL1BCL2L2
SCHEMBL24248787 0.85 LMNA (0.39) LMNABCL2BCL2L1MCL1BCL2L2
SCHEMBL1245081 0.80 LMNA (0.42) LMNABCL2BCL2L1MCL1BCL2L2
SCHEMBL23230285 0.80 LMNA (0.44) LMNABCL2BCL2L1MCL1BCL2L2
SCHEMBL18272086 0.77 LMNA (0.35) LMNA
SCHEMBL15743959 0.75 BCL2 (0.46) LMNABCL2BCL2L1MCL1BCL2L2
SCHEMBL9670626 0.75 ACHE (0.43) LMNATRPA1PTGS1ACHEALDH1A1
SCHEMBL5587005 0.73 SELL (0.48) LMNATRPA1PTGS1ACHEALDH1A1
SCHEMBL24248982 0.72 SELL (0.48) LMNABCL2BCL2L1MCL1BCL2L2
SCHEMBL24681025 0.72 TRPA1 (0.42) LMNABCL2BCL2L1MCL1BCL2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227474-A1 COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING RBM17, SF3B1, SF3B5 LMNA 301/4885BCL2 4295/4885BCL2L1 4150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.